<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716231</url>
  </required_header>
  <id_info>
    <org_study_id>VT-001-0050</org_study_id>
    <nct_id>NCT04716231</nct_id>
  </id_info>
  <brief_title>Atacicept in Subjects With IgA Nephropathy</brief_title>
  <acronym>ORIGIN</acronym>
  <official_title>A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IGAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vera Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the effect of atacicept compared to placebo on&#xD;
      change in proteinuria in adult subjects with IGAN.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will assess multiple doses of atacicept vs. placebo on impact of renal function as&#xD;
      measured by proteinuria. Safety, eGFR, serum immunoglobulins and gd-IgA1 will also be&#xD;
      clinically assessed. The clinical study is comprised of a 36wk double-blind treatment period,&#xD;
      followed by a 60wk open-label treatment period and a 26wk safety follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in urine protein to creatinine ratio (UPCR)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>UPCR based on 24 hour urine collection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urine protein to creatinine ratio (UPCR)</measure>
    <time_frame>36 Weeks</time_frame>
    <description>UPCR based on 24 hour urine collection</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in urine protein to creatinine ratio (UPCR)</measure>
    <time_frame>12, 48, 96 Weeks and Week 26 follow up</time_frame>
    <description>UPCR based on 24 hour urine collection</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in estimated glomerular filtration rage (eGFR)</measure>
    <time_frame>12, 24, 36, 48, 96 Weeks and 26 Week follow up</time_frame>
    <description>eGFR calculated by CKD-EPI formula</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in IgA, IgG, IgM, C3, C4 and Gd-IgA1 levels</measure>
    <time_frame>12, 24, 36, 48, 96 Weeks</time_frame>
    <description>Serum measurement of IgA, IgG, IgM, C3, C4 and Gd-IgA1</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events during the double-blind treatment period</measure>
    <time_frame>Through 36 Weeks</time_frame>
    <description>Safety and tolerability</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate serum PK of atacicept</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Serum concentration of atacicept</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>IgA Nephropathy</condition>
  <condition>Berger Disease</condition>
  <arm_group>
    <arm_group_label>Atacicept Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atacicept Dose A once weekly subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atacicept Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atacicept Dose B once weekly subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atacicept Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atacicept C once weekly subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match Atacicept</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match Atacicept once weekly subcutaneous (SC) injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Atacicept</intervention_name>
    <description>Once weekly subcutaneous (SC) injections by prefilled syringe</description>
    <arm_group_label>Atacicept Dose A</arm_group_label>
    <arm_group_label>Atacicept Dose B</arm_group_label>
    <arm_group_label>Atacicept Dose C</arm_group_label>
    <other_name>VT-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo to match Atacicept</intervention_name>
    <description>Once weekly subcutaneous (SC) injections by prefilled syringe</description>
    <arm_group_label>Placebo to match Atacicept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Must have the ability to understand and sign a written informed consent form&#xD;
&#xD;
          2. Male or female of ≥18 years of age&#xD;
&#xD;
          3. Diagnosis of IgAN as demonstrated by renal biopsy conducted within 10 years&#xD;
&#xD;
          4. Total urine protein excretion ≥ 1g per 24-hour or urine protein to creatinine ratio&#xD;
             (UPCR) ≥ 1 mg/mg (≥100 mg/mmol) based on a 24-hour urine sample during the Screening&#xD;
             Period&#xD;
&#xD;
          5. eGFR ≥ 30 mL/min/1.73 m2, as per the Chronic Kidney Disease Epidemiology Collaboration&#xD;
             (CKD-EPI) equation.&#xD;
&#xD;
          6. On a stable prescribed regimen of RAASi for at least 12 weeks that is at the maximum&#xD;
             labeled or tolerated dose&#xD;
&#xD;
          7. Systolic blood pressure ≤150 mmHg and diastolic blood pressure ≤90 mmHg&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. IgAN secondary to another condition (e.g., liver cirrhosis), or other causes of&#xD;
             mesangial IgA deposition including IgA vasculitis (i.e., Henoch-Schonlein purpura),&#xD;
             systemic lupus erythematosus (SLE), dermatitis herpetiformis, ankylosing spondylitis&#xD;
&#xD;
          2. Evidence of rapidly progressive glomerulonephritis (loss of ≥ 50% of eGFR within 3&#xD;
             months of screening)&#xD;
&#xD;
          3. Evidence of nephrotic syndrome within 6 months of screening (serum albumin &lt;30g/L in&#xD;
             association with UPCR &gt;3.5 mg/mg [350 mg/mmol]&#xD;
&#xD;
          4. Total urine protein excretion ≥ 5g per 24-hour or urine protein to creatinine ratio&#xD;
             (UPCR) ≥ 5 mg/mg (≥500 mg/mmol) based on a 24-hour urine sample during the Screening&#xD;
             Period&#xD;
&#xD;
          5. Renal or other organ transplantation prior to, or expected during the study&#xD;
&#xD;
          6. Concomitant chronic renal disease in addition to IgAN&#xD;
&#xD;
          7. Uncontrolled diabetes, defined as hemoglobin-A1c (HbA1c) &gt;7.5% at screening&#xD;
&#xD;
          8. History of tuberculosis (TB), untreated latent TB infection (LTBI), or evidence of&#xD;
             active TB determined by a positive Quantiferon test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Curley</last_name>
    <role>Study Director</role>
    <affiliation>Chief Development Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vera Therapeutics, Inc. Clinical Trials Information</last_name>
    <phone>650-770-0077</phone>
    <email>clinicaltrials@veratx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vera Site #107</name>
      <address>
        <city>Arvada</city>
        <state>Colorado</state>
        <zip>80002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Perez</last_name>
      <phone>303-232-3366</phone>
      <email>CPerez@WestNeph.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #103</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassidy Bowen</last_name>
      <email>cassidy-bowen@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #102</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Snyder</last_name>
      <phone>313-916-1931</phone>
      <email>rsnyder7@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #114</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hemangini Shah</last_name>
      <phone>505-998-7460</phone>
      <email>hema.s@renalmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #101</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Johnson</last_name>
      <phone>828-258-8545</phone>
      <email>taraj@mtnkidney.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #105</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Hanzl</last_name>
      <phone>610-433-4100</phone>
      <email>steph.hanzl@necresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #113</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Gallagher</last_name>
      <phone>215-955-8184</phone>
      <email>Barbara.Gallagher@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #112</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Marie O'Mara</last_name>
      <phone>401-444-5212</phone>
      <email>aomara@lifespan.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #110</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Fairhurst</last_name>
      <phone>802-847-4095</phone>
      <email>penny.fairhurst@uvmhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #904</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penelope Murie</last_name>
      <phone>+612 8890 6848</phone>
      <email>Penelope.Murie@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #203</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Rokegem</last_name>
      <phone>09/3326168</phone>
      <email>kelly.rokegem@uzgent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #201</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Damascène Barahira</last_name>
      <phone>3243667405</phone>
      <email>jdbarahira@chu.ulg.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #711</name>
      <address>
        <city>Jaipur</city>
        <zip>3022018</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mukesh Kumar Sharma</last_name>
      <phone>-9351791708</phone>
      <email>MKSHARMA1960@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #806</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hwayoung Lee</last_name>
      <email>dlghkdud1225@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #805</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sangmi Oh</last_name>
      <email>jinmi0320@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #803</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Jin Lee</last_name>
      <phone>82-10-4629-2328</phone>
      <email>truesasm@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #804</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Jung-Hee</last_name>
      <phone>82-10-9388-2492</phone>
      <email>kjhksw78@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #807</name>
      <address>
        <city>Seoul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeon Mi Jung</last_name>
      <phone>82-2-2228-0557</phone>
      <email>sevctc@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #403</name>
      <address>
        <city>Aydın</city>
        <zip>9100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekin Lacin</last_name>
      <email>ekin.lacin@medex-smo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #402</name>
      <address>
        <city>Kocaeli</city>
        <zip>41000</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eda Baykal Sari</last_name>
      <email>eda.sari@medex-smo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #504</name>
      <address>
        <city>Bristol</city>
        <zip>BS105NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie Jones</last_name>
      <phone>01174148122</phone>
      <email>Stefanie.Jones@nbt.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #503</name>
      <address>
        <city>Canterbury</city>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma Hector</last_name>
      <email>gemma.hector@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vera Site #508</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara McLaren</last_name>
      <phone>0141 232 7600</phone>
      <email>Barbara.mclaren@ggc.scot.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.veratx.com</url>
    <description>Vera Therapeutics, Inc Company Website</description>
  </link>
  <link>
    <url>https://theoriginiganstudy.com/</url>
    <description>Origin Study Website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Berger Disease</keyword>
  <keyword>Berger's Disease</keyword>
  <keyword>IGA Glomerulonephritis</keyword>
  <keyword>IGA Nephropathy</keyword>
  <keyword>Iga Nephropathy 1</keyword>
  <keyword>Immunoglobulin A Nephropathy Nephritis</keyword>
  <keyword>IGA Type Nephropathy, IGA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

